Risk of bleeding after endoscopic submucosal dissection for colorectal tumors in patients with continued use of low-dose aspirin

Abstract

Our data suggest that continued use of LDA increased the risk of bleeding after ESD for colorectal tumors compared with nonuse of anticoagulant/antiplatelets. No significant difference was seen between the LDA-continued group and the LDA-interrupted group.

Continued use of low-dose aspirin may increase risk of bleeding after gastrointestinal endoscopic submucosal dissection: A meta-analysis

“…Five full-text studies were chosen for the final analysis (10,11,(24)(25)(26) (Figure 1). The Newcastle-Ottawa scale was used to assess the quality of the included studies (Table 1).…”

“…The five selected publications included four historical cohort studies and one case-control study (10,11,(24)(25)(26). Four studies involved gastric cancer and one involved colorectal cancer; four studies described tumor location and tumor size and two mentioned operation time and rate of perforation; all the studies were published from 2012 to 2015 (10,11,24,26) (Table 2).…”

“…Four studies involved gastric cancer and one involved colorectal cancer; four studies described tumor location and tumor size and two mentioned operation time and rate of perforation; all the studies were published from 2012 to 2015 (10,11,24,26) (Table 2). The information on age was introduced in five publications.…”

“…Five studies with data available on bleeding included 271 patients who received LDA-continued treatment for thromboembolic events before and after ESD therapies; they also included 278 controls who received LDA-interrupted treatment (10,11,(24)(25)(26). The average incidence of bleeding in the LDAcontinued group was up to 11.8% but was 5.4% in the LDA-interrupted group.…”

“…Three of the trials with data available on bleeding included 171 patients who perioperatively received LDA-interrupted treatment and 2321 controls who did not use anticoagulant/ APT agents (10,11,26). In the no-anticoagulant/APT group, the incidence of bleeding was 4.8%, but was 5.8% in the LDAinterrupted group.…”